title: The management of familial hypercholesterolaemia in Morocco.
abstract: Familial hypercholesterolaemia (FH) is an autosomal dominant disorder characterized by high levels of low-density lipoprotein cholesterol (LDL-C) as a result of mutations that impair their removal from plasma.The clinical consequence is a high risk of premature cardiovascular disease. Because of the extreme risk of mortality and morbidity, diagnosis, recruitment and management of FH patients must be one of the priorities of public health. In Morocco, specialized consultation for dyslipidaemia and strategy for management of this cardiovascular major risk factor does not exist, making FH identification and management difficult. In this review, we present the first FH state of the art in our country through a sample of 66 subjects. By this analysis, we have tried to elucidate some points that impede the identification and recruitment of heterozygous FH and the management of both heterozygous and homozygous FH in Morocco. Also, we have attempted to propose some strategies for an adequate management of FH in our country, taking into account the local specifications.
authors.affiliation: Groupe de Génétique et Biologie Moléculaire, Laboratoire de Biochimie, Faculté des Sciences Aïn Chock, Casablanca , Morocco. elmessal@yahoo.fr
authors.forename: Mariame
authors.initials: M
authors.lastname: El Messal
authors.forename: Karima
authors.initials: K
authors.lastname: Aït Chihab
authors.forename: Rachid
authors.initials: R
authors.lastname: Chater
authors.forename: Mohamed
authors.initials: M
authors.lastname: Loutfi
authors.forename: Anas
authors.initials: A
authors.lastname: Kettani
authors.forename: Aïcha
authors.initials: A
authors.lastname: Hafidi
authors.forename: Ahmed
authors.initials: A
authors.lastname: Adlouni
mesh_terms: D001055:Apolipoproteins B / Q000235:genetics; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D003324:Coronary Artery Disease / Q000097:blood / Q000209:etiology / Q000235:genetics / Q000517:prevention & control; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009018:Morocco; D009154:Mutation; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D011973:Receptors, LDL / Q000235:genetics; D012697:Serine Endopeptidases / Q000235:genetics
chemical_list: D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D011973:Receptors, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases